Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.
Yumi TsuchiyaHiroshi TamuraKoji FujiiHirotaka NumaguchiKiichiro ToyoizumiTina LiuMathieu Le GarsVicky CárdenasTakashi EtoPublished in: Vaccine (2023)
A single dose and homologous Ad26.COV2.S booster increased antibody responses with an acceptable safety profile in Japanese adults (ClinicalTrials.gov Identifier: NCT04509947).